Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.570 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
3 Soaring Biotech Stocks That Could Climb Much Higher
These drugmakers have bucked the overall market's downward trend this year and expectations are still high. 
Via The Motley Fool
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Pliant Therapeutics Inc. (NASDAQ: PLRX) Climbs to New 52-Week High
Via Investor Brand Network
Where Pliant Therapeutics Stands With Analysts
Analysts have provided the following ratings for Pliant Therapeutics (NASDAQ:PLRX) within the last quarter: 
Via Benzinga
Expert Ratings for Pliant Therapeutics
  Within the last quarter, Pliant Therapeutics (NASDAQ:PLRX) has observed the following analyst ratings: 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
Upgrades 
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector. 
Via InvestorPlace
Pliant Therapeutics Secures FDA Fast Track Status For Liver Disease Drug
Pliant Therapeutics (NASDAQ: PLRX) received Fast Track designation for its lead asset PLN-74809 from the U.S. Food and Drug Administration (FDA) for the potential treatment of primary sclerosing... 
Via Benzinga
4 Analysts Have This to Say About Pliant Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Pliant Therapeutics (NASDAQ:PLRX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
Via Benzinga
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Short Volatility Alert: Pliant Therapeutics, Inc.
On Monday, shares of Pliant Therapeutics, Inc. (NASDAQ: PLRX) experienced volatile short activity. After the activity, the stock price went up +159.01% to $23.00. The overall sentiment for PLRX has... 
Via Benzinga
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
What's Going On With Pliant Therapeutics Stock?
Pliant Therapeutics Inc (NASDAQ: PLRX) shares are trading lower Tuesday after the company announced a proposed $150 million offering. 
Via Benzinga
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media. 
Via Benzinga
After-Hours Alert: Why Pliant Therapeutics Stock Is Moving
Pliant Therapeutics Inc (NASDAQ: PLRX) shares are volatile in Monday's after-hours session after the company announced a proposed $150 million offering. 
Via Benzinga
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Stocks Lower Midday as Tech Slumps
Stocks are lower midday, with the Dow Jones Industrial Average and Nasdaq Composite both down triple digits, as investors prepare for this week's inflation data and the start of earnings season. 
Via Talk Markets
Pliant Therapeutics Stock Just Doubled And Hit A 10-Month High — Here's Why
The company's IPF treatment is proving itself where others didn't. 
Via Investor's Business Daily
Nasdaq Tumbles 2%; Pliant Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading following the release of jobs report on Friday. 
Via Benzinga
Why These Casino Stocks Are Moving Lower, Here's 45 Stocks Moving In Monday's Mid-Day Session
Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study. 
Via Benzinga
Why U.S. Stocks Are Trading Lower; AZZ Earnings And More
U.S. stocks traded lower this morning as investors digested the recent jobs report for the month of June. 
Via Benzinga
Why Is Pliant Therapeutics (PLRX) Stock Soaring Today?
Pliant Therapeutics (PLRX) stock is rocketing higher on Monday after revealing data from a Phase 2 clinical trial of PLN-74809. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.